PAVE Trial Update

The PAVE trial, evaluating drug coated angioplasty balloons for AV fistulas in dialysis patients, has reached its recruitment target with a total of 212 patients being randomised to the trial.  It is funded by the NIHR/MRC Efficacy and Mechanism Evaluation (EME) programme, a MRC and NIHR partnership, and includes 19 UK sites, across England, Wales and Scotland.

Chief Investigator, Michael Robson said; “We are delighted to have reached this milestone, and are very grateful to the nurses, radiologists, nephrologists and surgeons around the UK who have worked hard to recruit patients.  We designed the trial so that only patients with a single lesion were randomised. Although this should give a clear answer regarding the efficacy of the intervention, it meant that many more patients than 212 had to be screened and consented.   Follow up will be complete in a year.”